1800 244 735

Helpline (02) 9874 9777

Coming soon: HD Therapeutics Conference 2012

An oasis of hope in the desert: the annual Huntington’s Disease Therapeutics Conference in Palm Springs, California, begins on 27th February. We’ll be bringing you live updates via Twitter and the web.

An exciting time

If 2011 is anything to go by, we predict that 2012 will be a big year for Huntington’s disease treatment research.

The new year has already brought exciting news of gene silencing success in primate trials and striking improvement in HD mice from injection of the ‘brain fat’ GM1.

Annual Therapeutics Conference

For the last 7 years the annual HD Therapeutics Conference in Palm Springs, California, has been a significant occasion for HD drug-hunters. It’s where the most exciting and cutting-edge treatment research is announced and discussed. It’s also a gathering of the world’s top HD researchers where ideas are shared and fruitful collaborations formed and nurtured.

The Conference begins very soon – Monday 27th February, to be exact. Your intrepid HDBuzz reporters Ed Wild and Jeff Carroll are going undercover at the Conference to bring you the latest news and buzz from the meeting.

The inside scoop from HDBuzz

Each day, we’ll be tweeting live updates from 9am to 6pm Pacific Time (that’s roughly 5pm to 2am in Europe). Follow @HDBuzzFeed on Twitter now, so you don’t miss anything.

If you prefer a daily digest, check HDBuzz.net or any of the HD sites that carry HDBuzz syndicated content. Each day’s news will be gathered together into a new article each evening, with our ever-popular ‘sunset conclusions’ to put things in context.

In the coming weeks, we’ll also bring you featured stories and interviews with some top scientists from the Conference.

Get in touch!

We want to hear from you, too, so send your questions, comments and queries to palmsprings@hdbuzz.net or tweet @HDBuzzFeed now or throughout the Conference.

So, get following, sign up for email updates and check the web frequently. Here’s looking forward to an inspiring Therapeutics Conference.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 8 January, 2021

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more

Uncovering the dark side of DNA repair to design HD treatments

Published date: 22 December, 2020

A gene known as ‘MSH3’, which encodes a protein involved in fixing and maintaining our DNA, has become a hot topic in Huntington’s research since being implicated as a key driver of the disease by multiple genetic studies. In a recent publication, a team of scientists from the National University of Ireland, Galway, have provided ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2

Published date: 1 November, 2020

The second day of the HSG conference was another busy day of presentations from HD researchers and clinicians. The day kicked off with a talk from Vaccinex who gave us an overview of their work on the SIGNAL clinical trial. Unfortunately, pepinemab, the medicine tested in this trial, did not influence HD symptoms and the ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 1

Published date: 30 October, 2020

The Huntington Study Group (HSG) is a clinical research network focused exclusively on HD. Yesterday the HSG annual conference began with a schedule jam-packed with virtual talks from researchers, clinicians and different companies who are all working towards finding new medicines for HD. The day encompassed many interesting presentations which covered a lot of the ... Read more

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more